MetLife, Inc. (MET) Earnings Call Transcript & Summary
August 6, 2026
What were the key takeaways from MetLife, Inc.'s August 6, 2026 earnings call?
In the second quarter of 2026, MetLife, Inc. reported adjusted earnings of approximately $1.6 billion, or $2.43 per share, reflecting a 15% increase year-over-year. The company achieved broad-based growth across all business segments, with notable contributions from Group Benefits and Asia, where adjusted earnings rose 25% and 21%, respectively. Management maintained a positive outlook, emphasizing that their New Frontier strategy is yielding strong results, and they announced a new $3 billion share repurchase authorization, indicating confidence in future performance.
What topics did MetLife, Inc. cover?
- Strong Earnings Growth: MetLife's adjusted earnings increased 15% year-over-year, with adjusted EPS growing 20%. Michel Khalaf stated, "This was an outstanding quarter and another clear demonstration of how our New Frontier strategy is working as intended."
- Group Benefits Performance: The Group Benefits segment generated adjusted earnings of $503 million, up 25% year-over-year, driven by favorable underwriting margins and volume growth. Khalaf noted, "The Group Life mortality ratio was 79%, reflecting continued improvement in mortality among the working age population."
- Asia Growth Momentum: Adjusted earnings from Asia increased 21% on a reported basis and 25% on a constant currency basis, with sales advancing 17%. Khalaf mentioned, "We see meaningful opportunities ahead" due to favorable demographics and product innovation.
- Capital Management and Share Buybacks: MetLife repurchased approximately $700 million of common shares in Q2 and announced a new $3 billion share repurchase authorization. McCallion stated, "These actions underscore the confidence in MetLife's earnings power, the strength of our balance sheet and our ability to generate durable free cash flow over time."
- Retirement and Income Solutions (RIS) Challenges: Adjusted earnings from RIS were up only 2% year-over-year, impacted by lower variable investment income. McCallion noted, "Total investment spread was 97 basis points in the second quarter, below our guidance range of 100 to 120 basis points."
What were MetLife, Inc.'s August 6, 2026 results?
- Group Benefits Adjusted Earnings: $503 million (+25% YoY)
- Asia Adjusted Earnings: $420 million (+21% YoY)
- Direct Expense Ratio: 12.1% (in line with target)
- Total Investment Spread: 97 basis points (below guidance range)
- Cash and Liquid Assets: $3.4 billion (within target buffer)
- Share Repurchase Authorization: $3 billion (new authorization)
MetLife's strong second quarter results reinforce the investment thesis, showcasing robust growth across multiple segments and effective capital management. However, challenges in the RIS segment and potential normalization of favorable mortality trends warrant close monitoring. Investors should watch for continued execution of the New Frontier strategy and the impact of macroeconomic factors on future performance.
Earnings Call Speaker Segments
Thanks, operator. Morning, everyone. We're glad you could be with us for MetLife's call covering the second quarter of 2026. Ahead of getting started, please take a look at the details regarding non-GAAP measures found in the investor relations portion of metlife.com, within our earnings release, our quarterly financial supplement, plus our earnings call and investor presentations — all of which you ought to review. Joining us today are Michel Khalaf, our President and Chief Executive Officer, alongside John McCallion, our Chief Financial Officer and Head of MetLife Investment Management. Additional senior management team members are also on hand to take part in the discussion; this morning, John McCallion will walk through the earnings call presentation that we published last night. That deck can be found on our website. Included in an appendix to the deck are disclosures, GAAP reconciliations, and other material, which you should review as well. Following our prepared remarks, we'll hold a Q&A session, and it will conclude right at the top of the hour. One reminder: kindly keep to a single question plus one follow-up. I'll now hand things over to Michel.
Thanks, John. Morning, everyone. We had a terrific quarter, and it shows once more that our New Frontier strategy is delivering exactly as we designed it to, and that our model can be repeated, grounded in a substantial base of recurring revenue plus the agility to put money to work wherever worldwide opportunities offer the best return for the risk involved. Two complementary profit engines sit at the core of New Frontier, and they add roughly the same amount. The first requires little capital: operations such as Group Benefits, Latin America, EMEA, and asset management produce appealing fee and underwriting income along with robust cash generation. The second is capital intensive: our retirement and spread-based operations draw on our origination, investment, and risk management expertise to deploy our balance sheet at appealing risk-adjusted yields. Crucially, each engine strengthens the other. The capital-driven side originates assets that MetLife Investment Management oversees, which fuels expansion of our asset management platform and grows our capital light earnings over time. Jointly, they produce an enterprise that is more balanced, more resilient, and positioned better to deliver across varying market conditions. That is precisely what we witnessed this quarter. Adjusted earnings rose in each business segment versus a year earlier. Underwriting results were robust. Volume gains were widespread, and we kept funding promising growth opportunities while also giving excess capital back to shareholders. This is New Frontier at work, using our scale, market-leading operations, and strategic diversification to deliver durable growth and appealing returns through a variety of economic environments. Now to second quarter results: we posted adjusted earnings of about $1.6 billion, or $2.43 per share. Adjusted earnings climbed 15% versus the prior year period. Adjusted earnings per share rose 20%, outpacing earnings growth, which mirrors our disciplined and steady approach to capital management. Adjusted premiums, fees, and other revenues, excluding pension risk transfers, grew 5% year-over-year. Sales climbed 7%, driven by robust gains across our international operations. Variable investment income came to $231 million pre-tax and exceeded the prior year period. Adjusted return on equity reached 17%, at the top end of our 15%-17% annual target range for a second consecutive quarter and comfortably above our cost of capital. Our direct expense ratio, which reflects both revenues and expenses, stood at 12.1%, matching our full-year target. We managed that even with roughly 50 basis points of impact from adding PineBridge Investments, a fee-based operation whose expense profile is structurally higher. While we integrate that business, we stay on target thanks to rigorous expense management and productivity gains from AI and other technologies. On that note, AI is turning into a structural advantage for MetLife, and our scale distinguishes us. The enormous number of new policies, service interactions, and claims we process daily gives us additional places to deploy AI and additional data to sharpen it. Over time, we anticipate that will become a meaningful and lasting tailwind for both growth and productivity, while delivering an even smoother experience for our customers. First, we keep a close eye on what we spend and invest in AI, including the cost of tokens and model usage; those outlays face the same return tests as anything else we fund or spend on. In growth, productivity, and customer service, the benefits we're seeing — clear in our direct expense ratio — are much larger than what we pay. And more than anything, how we govern AI and oversee its risks stays at the core of our deployment approach, in line with the confidence MetLife customers have in us. Now to segment results, beginning with Group Benefits, where adjusted earnings came to $503 million, a 25% rise versus the prior year. Life underwriting proved especially strong. At 79%, the group life mortality ratio showed ongoing gains in mortality for the working-age population. Adjusted PFOs were up 1%. Leaving out participating contracts, adjusted PFOs climbed 4%. Sales so far this year have grown 9%, and the regional business is ahead 11%, paced by the market of employers with under 1,000 workers. Year-to-date, we recorded double-digit sales growth in disability and voluntary products, with standout strength in A&H; these figures show how solid this flagship franchise is. Our scale, wide product range, and enduring customer ties distinguish us and leave us well placed to serve employers' and employees' changing needs, all while producing sensible growth as time goes on. Shifting to Retirement & Income Solutions, or RIS, adjusted earnings were $377 million, 2% above the prior-year figure. Adjusted PFOs, once pension risk transfers are excluded, grew 19%, mostly on U.K. longevity reinsurance and structured settlement sales. The long-term retirement chance here is still very attractive. As populations age, appetite rises for retirement income and risk transfer answers, and MetLife brings the origination skills, investment know-how, and product range to meet that appetite in major worldwide markets. Risk transfer, pensions, annuities, stable value, and other global risk solutions all sit within our portfolio. That range gives MetLife room to be choosy about where capital goes, taking on only those opportunities with the best risk-adjusted returns. Now to Asia, where adjusted earnings reached $420 million, climbing 21% as reported and 25% in constant currency terms. Sales grew 17% in constant currency, showing strong results everywhere, notably Korea, where momentum continues. Japan was up against a solid life and annuities sales quarter from a year earlier, yet posted nearly 90% A&H growth in constant currency after a medical product launch. Product sales split about evenly between US dollars and yen, which shows the balanced growth we're generating, tied to no one product or currency. Favorable demographics, extensive distribution, and ongoing product innovation leave meaningful opportunities ahead in our view. In Latin America, adjusted earnings hit $268 million, a record for any quarter and up 15%, or 4% in constant currency. Adjusted PFOs rose 6% in constant currency, on strong growth and healthy persistency throughout the region. Sales were 9% higher on that same basis. Latin America keeps showing why our top-tier market positions matter, along with our diversified distribution channels and our capacity to meet rising demand for protection, health, and retirement offerings. Moving to EMEA, adjusted earnings came in at $108 million, which was up 8%, or 11% when you strip out currency effects. Adjusted PFOs rose 12% on a constant currency basis, driven by sales and renewal activity throughout the region. Sales were up 15%, which speaks to steady, wide-ranging growth. Now on to MetLife Investment Management, or MIM, where the segment produced adjusted earnings of $57 million, an increase of 6%. That growth came from the contribution of integrating PineBridge Investments and Expense Management. Other revenues climbed 34%, and total assets under management hit roughly $748 billion. Our second quarter results show the benefit of diversification. Various businesses add value in various ways, yet collectively each one gains from the scale and capabilities of the wider MetLife organization. Turning to cash and capital, MetLife keeps operating from a place of financial strength. In the quarter, we bought back about $700 million of common shares. Year-to-date, through July, we've returned more than $2.4 billion to MetLife shareholders via stock buybacks combined with common dividends. Last night, we unveiled a fresh $3 billion share repurchase authorization, which reflects our confidence in MetLife's capital generation and long-term outlook. We finished the quarter with $3.4 billion of cash and liquid assets at our holding companies, solidly inside our $3 billion-$4 billion target buffer. Our stance on capital deployment and allocation hasn't changed. Our top priority is funding responsible organic growth, where MetLife holds structural advantages and chances to earn appealing risk-adjusted returns; we'll make inorganic investments when they bring strategic capabilities, satisfy our financial criteria, and build value. Past those opportunities, we give excess capital back to shareholders over time. We're also leveraging reinsurance and third-party capital to back additional retirement origination while generating assets for MIM to manage; this lets us chase customer demand in a more capital-efficient way and stretch the value of our platform across the enterprise. Above all, growth is turning into real shareholder value. Disciplined strategic capital deployment powers future earnings, and robust recurring free cash flow lets us invest in our businesses while also returning capital consistently. To wrap up, this was a superb quarter that yet again proved the investment case for MetLife under New Frontier. Our complementary earnings engines, capital light and capital driven, are functioning together as planned. They produce a more balanced and resilient earnings profile, plus a sturdier foundation for long-term value creation. We're happy with our progress; we have confidence in the strengths we've built over time, the momentum across our businesses, and our ability to execute through a range of environments. New Frontier is the right strategy for MetLife, and we're moving forward with speed and purpose. With that, I'll turn it over to John to walk through the results in more detail.
Thanks, Michel, and good morning to all of you. What we see in this quarter is yet another powerful illustration of MetLife's capacity to generate earnings and the robustness of our business model. We achieved widespread expansion throughout the company, posted outstanding underwriting outcomes, kept our expense discipline intact, and stayed prudent in how we put capital to work. I'll begin on page three of the earnings call presentation and go through the main factors behind the second quarter's results. It was a terrific quarter, and growth returns paired with execution allowed us once more to satisfy or surpass our key financial commitments. Adjusted EPS rose 20%, and adjusted ROE hit 17%, sitting at the upper bound of our 15%-17% target range. Our direct expense ratio came in at 12.1%, which keeps us positioned to beat our 12.1% 2026 annual target. Net income came to $705 million, or $1.09 per share, and adjusted earnings were $1.6 billion, or $2.43 per share. What separated net income from adjusted earnings was largely mark-to-market accounting on our derivatives along with net investment losses. On the whole, our credit outlook stays stable, and our hedging program is shaping up as anticipated. Turning to page four, adjusted earnings rose 15% year-over-year, or 14% on a constant currency basis. The growth was even across the company, fueled by favorable underwriting margins, robust volume growth in every segment, and higher investment margins, partly offset by less favorable expense margins. Adjusted earnings per share climbed 20% and 19% on a constant currency basis, with solid earnings growth backed by disciplined capital management. Now to the businesses. Group Benefits delivered a superb quarter, producing adjusted earnings of $503 million, up 25% year-over-year, fueled by favorable underwriting margins and volume growth. The Group Life mortality ratio stood at 79% for the quarter, beating our 2026 target range of 83%-88%, which speaks to continued favorable mortality trends among the working-age population. The Non-Medical Health interest adjusted benefit ratio was 73.9%, inside our annual target range of 70%-75%, and a 190 basis point improvement sequentially, in line with our seasonal utilization patterns. Growth remains healthy throughout the franchise. Sales rose 9% year-to-date, and adjusted PFOs increased 1% and up 4% excluding participating contracts, reflecting growth in both national accounts and regional business. Now for RIS, adjusted earnings were $377 million, up 2% year-over-year, fueled by favorable recurring interest margins and volume growth, partly offset by lower variable investment income. Total investment spread was 97 basis points in the second quarter, under our guidance range of 100 to 120 basis points, driven by weaker private equity returns within VII. While core spread excluding VI was 100 basis points, up 5 basis points sequentially, reflecting the benefit of asset deployment along with improved real estate equity income. RIS keeps gaining from the strength of its origination platform. RIS adjusted PFOs, excluding pension risk transfers, were up 19%, driven by strong growth in U.K. longevity reinsurance and structured settlements. Our retained liability exposures expanded by 3% compared to a year earlier, landing at the bottom of the range we projected for 2026, which aligns with what we anticipated — growth picking up as the year progresses. What's key is that despite a softer PRT market during the first half of 2026, the team kept pushing forward on other avenues for growth throughout the platform. A great illustration of this is U.K. funded Re. It highlights how we can draw on capabilities we already have, build new offerings, and generate appealing growth prospects even when some markets tighten up. In Asia, adjusted earnings reached $420 million, an increase of 21%, or 25% when measured on a constant currency basis. The results demonstrate underlying strength throughout the business, aided by positive equity markets, greater variable investment income, and ongoing volume expansion. Asia's main top-line growth indicators maintained their robust momentum during Q2. General account assets under management at amortized costs climbed 6% on a constant currency basis. Sales jumped 17% on a constant currency basis, driven by equity market tailwinds in Korea along with momentum from products launched recently. Over in Japan, sales grew 2% versus the same period last year, coming off a tough comparison, and rose 13% from the prior quarter. All together, these outcomes strengthen our belief in Asia's long-term growth path and the power of our franchise throughout the region. Latin America posted adjusted earnings of $268 million, a 15% increase year-over-year, or 4% on a constant currency basis. The results came from robust volume growth plus favorable market conditions, such as an elevated INCA return of 5.6% during the second quarter and reduced taxes. This was partly counterbalanced by the Mexico VAT change. Top-line momentum stayed solid, with sales rising 9% on a constant currency basis and adjusted PFOs climbing 16%, or 6% on a constant currency basis. Growth was widespread throughout the region, with Brazil, Mexico, and Chile leading the way. We keep identifying appealing growth prospects across the region, backed by strong distribution, healthy demand for products, and the expanding footprint of our MetLife Xcelerator platform. EMEA posted adjusted earnings of $108 million, an 8% increase year-over-year, or 11% on a constant currency basis. The results stemmed from robust volume growth, partly offset by greater expenses during the quarter. EMEA's top line stayed strong, with adjusted PFOs rising 12%, lifted by sustained sales momentum and steady renewal activity throughout the region. Sales grew 15% on a constant currency basis, mirroring broad-based gains across markets and geographies. What's important is that as the business keeps scaling, we're observing that growth converting into earnings power that is more and more consistent and durable. Now switching to MetLife Investment Management, or MIM, adjusted earnings came in at $57 million, up 6%, propelled by solid business growth and expense management. Momentum is growing throughout the platform, and with integration benefits still materializing, we anticipate adjusted earnings will keep moving upward during the second half of the year. Total AUM rose $12 billion quarter-over-quarter to $748 billion as of June 30th, which includes a noteworthy $7 billion gain in institutional client AUM. That expansion, paired with a 410 basis point gain in operating margin for the quarter, puts MIM in position to hit full-year adjusted earnings inside its guidance range of $240 million-$280 million. While probably closer to the low end, our confidence in this business's continued success has not wavered, and our 2027 guidance is still intact. Corporate & Other posted an adjusted loss of $160 million in the second quarter, versus a loss of $142 million a year ago. The change from the prior year mainly came from foregone earnings tied to last year's strategic reinsurance transactions along with market-related employee costs. Favorable life underwriting margins partially offset those impacts. The company's effective tax rate on adjusted earnings for the quarter came in at 23%, under our 2026 guidance range of 24%-26%. Turning now to page five, pre-tax variable investment income totaled $231 million in the second quarter of 2026. The results fell short of the implied quarterly run rate, largely due to lower private equity returns, with an average return of 0.8% and real estate and other funds average returns of 1.1%. As a reminder, private equity and real estate and other funds are reported on a one-quarter lag and accounted for on a mark-to-market basis. Going forward, we anticipate stronger private equity returns in the third quarter, especially from our venture capital investments, helped by elevated IPO activity and higher public market valuations.
On page six, we present after-tax VII broken out by segment along with Corporate & Other across the last five quarters. Most of our VII assets sit in Asia, RIS, and Corporate & Other, which aligns with how long these obligations run. Although VII may fluctuate quarter to quarter, we run the business seeking normalized returns across time and stay at ease with our outlook for the full year. Turning now to page seven and expenses. For Q2 2026, our direct expense ratio came in at 12.1%. That's versus 11.7% for the entirety of 2025 and also 11.7% in last year's second quarter. Robust PFO growth plus ongoing cost discipline let us take on the roughly 50 basis point hit from the PineBridge acquisition that we had already flagged. We oversee costs on a full-year basis and stay confident about surpassing our 2026 goal of 12.1%. Our steady cost execution remains something that sets MetLife apart, bolstering how durable our earnings are and our capacity to put money into growth while still meeting our financial promises. Onto slide eight, MetLife keeps running from a place of solid capital and healthy liquidity. At June 30th, cash and liquid assets held at the parent companies came to $3.4 billion, which sits inside our $3 billion-$4 billion target cash buffer. During the second quarter, we gave back roughly $1.1 billion to shareholders, and that included about $700 million of buybacks. In July, we bought back an extra approximately $225 million of shares. Such moves highlight faith in MetLife's earnings power, how strong our balance sheet is, and our knack for producing lasting free cash flow across time. When it comes to our U.S. companies, we figure total statutory adjusted capital on an NAIC basis at about $16.4 billion as of June 30th, 2026, which is 1% higher than March 31, 2026. Last, in Japan, we now anticipate our initial economic solvency ratio, or ESR, landing at the top end of a 170%-190% range for the fiscal year that ended March 31st, 2026, above our earlier expectation of the middle of the range. Though results will shift year to year, we're at ease running ESR anywhere inside this range. To sum up, MetLife turned in a superb second quarter. We achieved strong, broad-based growth, generated appealing returns, kept up disciplined cost management, and went on deploying capital from a place of strength. Equally important, performance throughout the enterprise drove these results, showcasing the quality, resilience, and diversification of our earnings. Looking ahead, we stay focused on carrying out our New Frontier strategy, meeting our commitments, and building long-term value for shareholders. With that, I'll hand the call back to the operator for your questions.
Hey, thanks. Good morning. My first question was on inorganic opportunities. You mentioned that in the prepared remarks, if it adds value and strategic fit. So, I suppose the question is: at this moment, looking at your business portfolio, which parts of the company might you want to add to if an opportunity arises?
Absolutely. Morning, Ryan, and thanks for asking. This is Michel. To begin with, I'd say our philosophy and approach to M&A haven't really shifted at all. M&A has always been something we see as a strategic capability. On your specific question, I've mentioned before that there are two areas where we'd potentially be inclined to look at M&A, and those are Asset Management and Group. Let me begin with Group. I'd say that while we don't perceive any gaps when it comes to our product set, which is the broadest in the industry, or our capabilities — we've put substantial investment into technology, as you're aware — that's really helping us push our competitive advantage even further. While we don't see any gaps there, we're constantly talking with our customers, trying to figure out whether there are things they'd be interested in that we might want to look at. You've watched us over recent years bring in pet insurance, for instance, and vision. More recently, an identity theft product has been added to what we offer. We're always willing to consider new capabilities or solutions, if that made sense. Even so, as I mentioned, we don't see any gaps when it comes to what we offer. The area that's more likely, I'd say, is asset management, and you saw us complete the PineBridge Investments deal late last year. Again, here, I'd want to stress that we'd be examining adjacencies or complementary capabilities rather than anything transformational. We have a solid path to growing this business organically, but we'd be open to supplementing that with inorganic complementary opportunities. Beyond that, I'd say we'll stay opportunistic outside these two areas. I'd also note that we have a track record of being highly disciplined with capital deployment and M&A, and we have a high bar to clear to make sure we create long-term value for our shareholders.
Thanks. My question concerns Group Life. Over the past two years or so, mortality has been favorable both for MetLife and for the broader industry. If that keeps up, do you believe there will be any need to share some of that favorability with customers by way of pricing moves? Is your view that if mortality stays favorable, you're able to hold price where it is?
Morning, Ryan. This is Ramy. Allow me a moment to discuss the quarter, and after that I'll address your pricing question. For several quarters now, we've observed favorable mortality; in this particular quarter, roughly 2 points of favorability showed up, driven by a mix of prior period development and claims severity coming in under expectations. Regard those 2 points as something we anticipate will normalize going forward. There's early evidence of that when you look at our July numbers. I simply want you to keep this quarter in perspective and anticipate moderation across the remainder of the year. As for your question, when I consider the overall results and the trend going forward, if this mortality favorability were to persist, you'd expect our margins to normalize gradually over time, though I'd stress how gradual that would be. In our Life book, this business has a renewal cycle of 3 to 5 years. Any normalization would play out across a number of years rather than in a quarter or as a 2027 type impact.
Thanks.
Hello there. Good morning to everyone. My initial inquiry is this: I picked up on your comment that mortality among working-age people helped drive solid Group Life outcomes. Could you discuss how mortality has looked across your other business blocks? What I have in mind is Individual Life as well as Corporate & Other, plus PRT and RIS. My understanding is that those policyholders tend to be older, but whatever insight you can offer would be greatly appreciated. Thanks so much.
Pablo, there's a great deal of interference coming through on your question. Would you mind trying to say it again, or check what might be behind that disruption?
Yep, sorry about that. Is this better?
Yes.
Yeah, okay. I'll try to slow down a bit more. You said working-age mortality helped drive strong Group Life results — I picked up on that. Could you discuss how mortality has looked across your other business segments? I have Individual Life and Corporate & Other, PRT and RIS in mind. My sense is those customers tend to be older, so results might differ, but I'd welcome whatever insight you can offer. Thanks.
Pablo, this is Ramy. Hearing you is still a challenge, but my understanding is your question concerns mortality outside the group operation, especially how things are unfolding within RIS. What I'd say is this: picture the RIS population as mostly comprised of older individuals, people who are retired. The gains we observe among those people align quite closely with the assumptions and reserve levels we've established. So from my standpoint, underwriting outcomes in RIS are coming through essentially as we anticipated. One thing worth pointing out: when you examine population-level data overall, gains among working-age groups have occurred much more rapidly than gains among those above 65; that pattern differs across the two groups. Beyond that, what matters for our numbers is the way we price and set reserves, and RIS results are tracking right in line with those pricing and reserving assumptions.
I just wanted to chime in there, Pablo. Broadly speaking, from what we can observe — and clearly we've had several years now of shifts in mortality — our contention is that things have largely returned to the path we were following before COVID, correct? Like Ramy mentioned, the decline is more pronounced among working-age people, and less so for retirees and the older demographic. On the whole, there's been an improvement. It does differ across age brackets, I'd say. But generally, we view ourselves as being back on that pre-COVID trajectory.
Alright. I hope nothing is interfering on my line. I'd like to turn to the PRT market. A few firms this earnings season have expressed some caution regarding full-year 2026 results compared with last year. I'm wondering whether you're observing the same pattern, what you believe is restraining the market, and what would need to occur for stronger growth going forward? Thanks.
Hey, good morning, Suneet. When you consider this market, particularly the segment we concentrate on — the jumbo market — it's inevitably going to be lumpy. I wouldn't attempt to read too much into any single quarter's activity, or even a full year, honestly. Look at how we've performed. We're coming off a record-setting 2025. We sold nearly $14 billion of PRTs during that year, with $12 billion of that arriving in the fourth quarter; that alone highlights how uneven the activity can be. The first half has been on the lighter side, especially within the jumbo space. We're seeing a more robust pipeline for the second half, with additional opportunities appearing for Q3 and Q4. Our approach to pricing this business will always remain disciplined, and we'll stay focused on delivering attractive risk-adjusted returns. I'd note that with PRT, you must always consider the macro backdrop, and that backdrop is extremely positive. There are $3 trillion in defined benefit pension assets, backed by solid funding levels, plus a very compelling industrial rationale for those corporates to shed that risk. We hold a leading position in that market, and we stand to benefit from it. Another thing I'd mention regarding PRT is that the same patterns unfolding in the U.S. market are also unfolding in the U.K. market. As Michel pointed out, we're diversified, capable of identifying other areas of growth, and that's precisely what we've accomplished so far this year. We've written over $1 billion of U.K.-funded reinsurance year-to-date. You can think of that as PRT delivered through reinsurance, and it's been achieved at attractive returns while contributing to our growth here. All things considered, when you take the entire RIS business into account, we have strong confidence that for the whole year we will stay inside our retained balance growth target of 3%-5%, which simply shows how strong our franchise is along with the product portfolio we hold.
All right, that's useful. Thank you. I'd like to shift over to Japan. It appears there is quite a bit happening over there with the Bank of Japan situation, plus yen and rate swings. The industry has a great deal to handle. Your sales appear to be rising consistently. I was hoping to get a clearer picture of how your model differs and whether some of this — call it turbulence occurring in Japan — provides an opening for you to push in a bit harder? Thank you.
Hi, Suneet. Lyndon speaking. Well, we're genuinely happy with how sales have performed throughout Asia, and not only in Japan. Looking at second quarter sales, they're higher by 17%, and on a year-to-date basis, sales have risen 19% compared with a year earlier. Solid results across every one of our franchises. What's actually behind that is the sustained momentum we've witnessed this year, the payoff from numerous actions we've carried out. We possess scale along with the diversification present in our distribution across virtually every market, and that's especially the case in markets such as Japan and Korea. We have product innovation. There's robust product development, covering both US dollar and local currency offerings. In US dollar, we were first to market with those. We truly have strong execution excellence in every market. It's the mix of these three drivers that is genuinely fueling our success in Japan. And not only there — throughout every market — and the results are visible across all of Asia. The market has experienced some volatility. We've observed a certain amount of yen volatility recently. Mostly, we find customers tend to hold back whenever there's considerable volatility. Our sales through June have remained strong. Moving into July, that momentum keeps going. We're genuinely well positioned thanks to all these key drivers in the market, and I believe that has truly been central to our success in the Asia story.
All right, thanks.
Morning. Hi, Michel — I'd like to return to the M&A topic briefly. I've heard what you said, Asset Management and Group Benefits, adjacent businesses and group; regarding that opportunistic remark, though, I believe there are some emerging market properties that, as we learned yesterday, will be put up for sale. In Latin America, I think you've previously completed two highly successful transactions. If such opportunities arose, would that be of interest?
Yes. Hi, Tom. I appreciate the question. We never discuss market speculation, and that isn't about to change. As I mentioned, our thinking on M&A remains exactly the same; we're constantly in the flow. Almost no deal reaching the market fails to pass across Adora Whitaker's desk. Clearly, we enjoy strong visibility into what's going on. I'd stress that our approach to M&A is highly disciplined. As I said, the bar to clear is high; we also weigh M&A against other possible uses of capital. That's my response. As for LATAM, let me simply add that our LATAM business has us very pleased. Eric and his team, I believe, have delivered truly exceptional work and keep doing so. Our results show that LATAM is well on track to produce $1 billion in earnings this year, which, incidentally, is about twice what it was before the pandemic. Sustained growth in the region is driving this. While we're seeing expansion throughout the region, our Brazil operation has ranked as the fastest-growing life insurer in that market, in that country, for a number of years now, and it currently accounts for roughly 20% of total LATAM sales. The momentum there pleases us greatly as well; that's all I can share.
All right, appreciate it, Michel. What I want to ask next is really about repositioning the portfolio in light of rates. We've seen significantly higher rates in Japan as well as the U.S. Have you started, or at least thought about, shifting the portfolio in either of those businesses? And even just mechanically, is it possible that base spreads could rise simply because of the rate levels, when you consider assets maturing and new money coming in across those geographies? Thanks.
Yeah. Morning, Tom. John here. Broadly, I'd start by saying we approach ALM and risk management with a certain mindset, and clearly, whenever a reinvestment opportunity arises, we draw on the combined strength of all our differentiated investment capabilities. What I'd add is that with matters like this, everything is evaluated at the margin. Simply altering the portfolio doesn't come without a cost. Take RIS as an example—we've noted that spreads have been relatively steady. That's partly because of the product mix diversification mentioned earlier. In Japan, our portfolio is now genuinely balanced between U.S. assets and yen. My view is that no sudden shift would ever take place, though as time passes, higher rates, as we've said previously, do create a form of favorable tailwind.
All right. Appreciate it.
Hey, morning. Can you share your most current views regarding private equity? We noticed you reduced that position somewhat during the most recent quarter, and it appears you've been reducing it somewhat across the past few quarters. Would you agree with that description, and might you explain the reasoning behind it? Thanks.
Morning, Wilma; John speaking. I believe we've mentioned this previously, and for us it's been something of a journey spanning multiple years, but the reality is that we're in what I'd call a comparatively elevated rate setting versus where things stood, say, a number of years back. We've discussed how, as time goes on, we'd likely hold a somewhat smaller allocation toward PE, though we're still putting money in, yet the runoff tends to move faster than the contributions. Then, as you pointed out for the first quarter, we acted opportunistically. We found a chance to complete a sale, while also retaining the ability to keep managing those funds on behalf of third parties, and to raise some extra capital in connection with that. Overall, I'd say the trajectory is a moderate decrease over time for PE, but that doesn't mean we'll keep investing in the space; rather, because of the seasoned nature of our portfolio and its diversification, we'd anticipate distributions exceeding contributions.
Okay. Thanks. Is Group PFO growth roughly 4%? I understand that's stronger than the industry—is that the level you aim for given current conditions, or do you intend to push it higher, closer to 7%? How is the market performing right now, and what possibilities exist for expansion? Appreciate it.
Thanks, Wilma; Ramy speaking. For the Group, from a revenue standpoint, what I'd highlight is that momentum looks quite strong, and every fundamental metric is favorable. We mentioned that sales have increased compared with the prior year. Looking at the under 1,000 segment, those are in fact higher versus last year by a substantial amount, comfortably into double-digit territory. Persistency has improved during this year. We noticed this especially within our dental block. The rate actions, which feed into those PFO figures as well, are tracking as we anticipated; we keep observing climbing participation rates among the employee population, along with ongoing double-digit expansion in the voluntary suite of products. Every one of those top-line signals is quite robust. Regarding that kind of 4%-7% range, view it as a figure spanning multiple years. In a particular year, we might land at the bottom, or at the top, of that range. Sales timing plays a role. There are jumbo sales, how large the cases we win happen to be, and so forth; we're happy with the growth, we're happy to be within the range, and we see genuinely strong momentum ahead across every market in this business.
Thanks a lot.
Hi there, morning. Ramy, would you mind giving us some detail about how Non-Medical Health performed during the quarter? What did dental and disability look like? I suppose PFML has been something of a focus area alongside others. What was your experience there this quarter?
Appreciate it, Joel. Perhaps I'll begin with PFML. What we saw unfold this quarter largely tracked what we laid out during our Q1 earnings call, as you might remember. For PFML products, the claims pattern involves heavier claims early on that generally settle down once a program has been in place for a few months. That's exactly what's happening now, and we observed reduced PFML submissions now that this run-in effect, so to speak, sits behind us. Meanwhile, as part of our BAU, whenever rate actions are needed for this business, we're applying suitable ones. Then, turning to disability briefly, if you zoom out and examine the total disability results for the quarter, those came in favorable. Incidents and recoveries matched what we anticipated, and we saw gains on a year-over-year basis. I'd call this no coincidence. It's quite deliberate, reflecting the investments we're putting into the business, the investments on the data analytics and AI side, which are fueling better recoveries and delivering these positive results for the quarter. Perhaps as one final step back, consider the total Non-Medical Health ratio. Dental is showing its usual seasonality, and that seasonality suggests the back half of the year will bring us stronger results, and thus a stronger Non-Medical health ratio overall versus the first half of the year. Hope that's useful.
All right, thanks. That was useful. Turning to Asia — you've kept pointing to AUM growth as a metric worth watching, and it's been solid. I'm curious about PFO growth, since that was really strong again this quarter. Can you share anything about what's behind the renewed pickup in PFO growth across Asia, and whether that can be sustained?
Hi Joel, Lyndon speaking. Well, ours is an AUM business. Our main emphasis is the retirement space. A large share of what we do lands in the AUM pieces. When it comes to growth in PFOs, we also offer certain FAS 60 style products. That portion of our business has been expanding. Some of it is showing up in the yen area, particularly as the yen product begins to gain traction, and as of now it accounts for more than 50% of our sales. Shen brought that up before. We'll begin to see PFOs more or less keep growing, though the majority of what we do remains centered on AUM. That's more or less the main thing fueling our growth.
Understood. Thanks a lot.
Morning, everyone. I'd like to pick up where we left off on RIS — the base spread widened by 5 basis points quarter over quarter, which strikes me as somewhat stronger than what people had anticipated coming into this period. Picking up on what Tom asked earlier, given the current level of rates, the reduced number of Fed cuts, and the higher-for-longer backdrop, what's your view on how base spreads will move through the second half of the year?
Morning, Wes. John here. As you point out, total spreads came in at 97 basis points, and that reflected weaker private equity returns, which we'd already flagged. Core spreads hit 100, landing at the upper bound of the new 95% to 100% range we laid out before. We'd discussed asset deployment, and we knew this was coming. This quarter we did see somewhat stronger real estate equity income, though that will probably give back some of that gain seasonally in Q3. Looking forward, we still believe 95 to 100 holds — even with where rates sit, we're positioned pretty well no matter what the curve does; we've managed to set ourselves up so that whether the curve steepens or simply remains flat, 95 to 100 still looks like a solid baseline. If we had to name a single figure for the third quarter, it would lean toward the middle of that range right now, purely because of how some real estate returns behave seasonally in 3Q.
Thanks, John. Let me ask about group mortality — results so far have been quite favorable. From what I gathered in your remarks, there appear to be a couple of points of normalization, and even after factoring those into Q3 and Q4, you'd still be maybe 2 or 3 points under the bottom of your range. Can you give any guidance on where that lands for the back half or the full year?
Sure. The ratio will always move around somewhat, but I'd note that the sharpest seasonality in the group mortality ratio tends to show up in Q1, driven by how severe the flu season is. Assuming today's trends hold and those normalization items I referred to come back, that's probably your best estimate. I'd direct you to the 2 points of normalization we saw this quarter, which we don't anticipate recurring in the second half.
Appreciate it.
Okay then. That appears to be all the time we have for this call. We appreciate everyone joining us, and enjoy the rest of your day. Thanks.
This concludes today's call. Thank you for attending. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete MetLife, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to MetLife, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.